Multiple primary cancers in BRCA1/2 carriers – A review of literature and our observations

An increasing number of patients with diagnosed synchronous or metachronous neoplasms that are gene as well as non-gene dependent which are associated with the development of new oncological treatment, and environmental factors, prompted the authors of this study to conduct an analysis in a narrow group of patients with multiple cancers and simultaneous BRCA1 mutations (confirmed by genetic analysis). BRCA1 mutation, as well as multiple cancers were found in seven patients treated between 2007 and 2013. The patients diagnosed with a second cancer shared a uniquely common trait – a 5382insC mutation. The study describes four patients that did not carry a BRCA1/2 mutation, yet were diagnosed with multiple cancers. A brief review of literature was performed concerning multiple cancers in women.

Synchronous; Metachronous; BRCA1/2 mutation; Multiple cancers.

[1] Jensen O.M., Parkin D.M., MacLennan R., Muir C.S., Skeet R.G.: “Cancer registration: principles and methods” (IARC Scientific Publication No. 95). Lyon, France: IARC, 1991.

[2] Altekruse S.F., Kosary C.L., Krapcho M., Neyman N., Aminou R., Waldron W., et al.: “SEER cancer statistics review, 1975–2007”. National Cancer Institute; Bethesda, MD: 2009. Based on November 2009 SEER data submission, posted to the SEER Web site, 2010.

[3] Lynch C.: “Section I: Biology, history, clinical significance. The biology of multiple primary cancers”. In: Howe L.H. A review of the definition for multiple primary cancers in the United States. Princeton, NJ: Workshop Proceedings from December 4-6, 2002, 2. Available at: http://prdupl02.ynet.co.il/forumfiles_2/19207389.pdf

[4] Wood M.E., Vogel V., Ng A., Foxhall L., Goodwin P., Travis L.B.: “Second malignant neoplasms: assessment andstrategies for risk reduction”. J. Clin. Oncol., 2012, 30, 3734.

[5] Noh J.M., Choi D.H., Baek H., Nam S.J., Lee J.E., Kim J.W., et al.: “Associations between BRCA mutations in high-risk breast cancer patients and familial cancers other than breast or ovary”. J. Breast Cancer, 2012, 15, 283.

[6] Shih HA., Nathanson, KL., Seal S., Collins N., Stratton MR., Rebbeck TR., et al.: “ BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers”. Clin. Cancer Res., 2000, 6, 4259.

[7] Lal G., Liu G., Schmocker B., Kaurah P., Ozcelik H., Narod S.A., et al.: “Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2”. Cancer Res., 2000, 60, 409.

[8] Lorenzo Bermejo J., Hemminiki K.: “Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing”. Ann. Oncol., 2004, 15, 1834.

[9] Górski B., Jakubowska A., Huzarski T., Byrski T., Gronwald J., Grzybowska E., et al.: “A high proportion of founder BRCA1 mutations in Polish breast cancer families”. Int. J. Cancer, 2004, 110, 683.

[10] Antoniou A.C., Gayther S.A., Stratton J.F., Ponder B.A., Easton D.F.: “Risk models for familial ovarian and breast cancer”. Genet. Epidemiol., 2000, 18, 173.

[11] Antoniou A., Pharoah P.D., Narod S., Risch H.A., Eyfjord J.E., Hopper J.L., et al.: “Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies”. Am. J. Hum. Genet., 2003, 72, 1117. Epub 2003 Apr 3.

[12] Goecke T., Schulmann K., Engel C., Holinski-Feder E., Pagenstecher C., Schackert HK., et al.: “Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch Syndrome: a report by the German HNPCC Consortium”. J. Clin. Oncol., 2006, 24, 4285.

[13] Ladopoulou A., Kroupis C., Konstantopoulou I., Ioannidou-Mouzaka L., Schofield A.C., Pantazidis A.: “Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed”. Cancer Lett., 2002, 185, 61.

[14] Santarosa M., Dolcetti R., Magri M.D., Crivellari D., Tibiletti M.G., Gallo A., et al.: “BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy”. Int. J. Cancer, 1999, 83, 5.

[15] Papp J., Raicevic L., Milasin J., Dimitrijevic B., Radulovic S., Olah E.: “Germline mutation analysis of BRCA1 and BRCA2 genes in Yugoslav breast/ovarian cancer families”. Oncol. Rep., 1999, 6, 1435.

[16] Yazici H., Bitisik O., Akisik E., Cabioglu N., Saip P., Muslumanoglu M., et al.: “BRCA1 and BRCA2 mutations in Turkish breast/ovarian families and young breast cancer patients”. Br. J. Cancer, 2000, 83, 737.

[17] Szabo C.I., King M.C: “Population genetics of BRCA1 and BRCA2”. Am. J. Hum. Genet., 1997, 60, 1013.

[18] Varley J.M: “Germline TP53 mutations and Li-Fraumeni syndrome”. Hum. Mutat., 2003, 21, 313.

[19] http://cancer.stanford.edu/information/geneticsAndCancer/types/cowden.html

[20] Scott R., Crooks R., Meldrum C: “Gene symbol: STK11. Disease: Peutz-Jeghers Syndrome”. Hum. Genet., 2008, 124, 300.

[21] Sanchez-Cespedes M.: “A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome”. Oncogene, 2007, 26, 7825.